Ocugen, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ocugen, Inc. on May 14, 2026. The report details the completion of a private offering of convertible senior notes and the full exercise of an over-allotment option.
Key Financial Metrics and Capital Structure
- Debt Issuance: The Company issued an additional $15.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034.
- Total Offering Size: Combined with the initial $115.0 million issued on May 7, 2026, the total aggregate principal amount of notes issued is $130.0 million.
- Interest Rate: 6.75% per annum.
- Maturity Date: 2034.
- Conversion Terms: Notes may not be converted prior to May 15, 2027, or the "reserved share effective date," whichever is earlier. Until the reserved share effective date occurs, conversions will be settled solely in cash.
- Potential Equity Dilution: Up to 8,108,108 shares of common stock may be issued upon conversion of the additional $15.0 million notes, based on a conversion rate of 540.5405 shares per $1,000 principal amount.
Material Changes
The primary material change is the increase in the Company's direct financial obligations due to the issuance of the additional $15.0 million in notes. This transaction represents the full exercise of the over-allotment option granted to the initial purchaser in the May 7, 2026 offering.
Outlook, Risks, and Unusual Items
- Regulatory Status: The additional notes were sold in reliance on exemptions from registration under Section 4(a)(2) and Rule 144A of the Securities Act of 1933.
- Settlement Risk: The Company retains the election to settle conversions in cash, shares, or a combination, subject to limitations. However, cash settlement is mandatory until the reserved share effective date.
- Disclosure: A press release announcing the closing was issued on May 14, 2026, and is incorporated by reference.
Investor Verification Checklist
- Verify the total outstanding principal of the 6.75% Convertible Senior Notes due 2034 ($130.0 million).
- Confirm the specific date of the "reserved share effective date" to understand when cash-only settlement restrictions may lift.
- Review the Indenture (Exhibit 4.1) for specific limitations on share issuance and conversion adjustments.
- Assess the impact of potential dilution from the maximum 8,108,108 shares issuable from the additional notes.
- Check the Company's liquidity position to ensure it can meet cash settlement obligations if conversions occur before the reserved share effective date.